Late sodium current Inhibitors
1 drugsAbout Late sodium current
The late sodium current (INaL) is a sustained inward sodium current during the cardiac action potential's plateau phase. Increased INaL can disrupt cellular electrophysiology. It has emerged as a drug target where cellular excitability plays a key role.
INaL modulation aims to restore normal cellular function and alleviate disease symptoms. Currently, there is no genetic evidence directly linking variations in genes encoding INaL components to specific diseases.
Ranolazine is the only FDA-approved drug modulating INaL. It is a small molecule approved in 2013 by I3 PHARMS for one indication in the 'other' therapeutic area.
Strategic Insights
ℹ️ How we calculate- White space opportunity in STEMI (ST Elevation MI) with only 1 trials.
- phase2 represents biological uncertainty with 50% completion.
Top Late sodium current Drugs
I3 PHARMS is the only company with an approved drug targeting INaL.
The market is highly concentrated, suggesting high barriers to entry or limited commercial interest.
Late sodium current Drug Modality Landscape
Modalities
Routes of Administration
Only one approved drug targets Late sodium current, using small molecule modality.
The absence of other modalities represents a whitespace opportunity for novel therapeutic approaches.
Late sodium current Clinical Trials 56 trials
Completion by Phase
| Phase | Total | Completed | Failed | Active | Completion |
|---|---|---|---|---|---|
| Phase 1 | 8 | 8 | 0 | 0 | 100% |
| Phase 2 | 22 | 12 | 7 | 3 | 63% |
| Phase 3 | 10 | 8 | 2 | 0 | 80% |
| Phase 4 | 16 | 10 | 6 | 0 | 63% |
Top Sponsors
By Modality
Top Conditions
Top Drugs
Late sodium current Drug Approval Timeline (2013 - 2013)
The first and only drug, Ranolazine, was approved in 2013.
The approval timeline suggests potential saturation or lack of recent innovation in this area.
Pro Intelligence Preview
Deep insights for drug target analysis
Competitive Landscape
- • 1 companies competing
- • Market share by company
Full Drug Portfolio
- • All 1 approved drugs
- • Approval dates & indications
Genetic Validation
- • Full genetic evidence table
- • Effect sizes & directions
Approval Timeline
- • Full 1-drug timeline
- • First-of-modality markers
Clinical Trials Analysis
- • Competition: High (15 sponsors)
- • White space: 10 underexplored indications
- • Success rates by condition
Full summary • All drugs • Genetic evidence • Trials • Timeline
How We Calculate These Metrics
Target Attractiveness Score
A 0-100 score based on trial activity, sponsor diversity, and completion rates. Calculated from 19 clinical trials targeting Late sodium current.
Completion rate: Percentage of trials that reached their planned endpoint. Trials terminated early, withdrawn, or suspended are not counted—these often indicate safety issues, lack of efficacy, or strategic pivots.
- Highly Attractive (80+): High trial activity, many sponsors, strong completion rates
- Attractive (60-79): Good trial activity and validation
- Moderate (40-59): Moderate interest from sponsors
- Low (under 40): Limited trial activity or validation concerns
Strategic Insights
Auto-generated insights based on trial analytics including competition intensity, white space opportunities, modality shifts, and failure patterns. We analyze trial sponsors, phases, indications, and outcomes.
Risk Signals
- High Competition: Many sponsors competing for this target (may reduce market opportunity)
- High Failure Risk: Low trial completion rates suggest development challenges
- Low Validation: Limited trial activity or poor outcomes indicate uncertain viability
- White Space Available: Underexplored indications present opportunities